Cystic Fibrosis Australia
PO Box 268 North Ryde NSW 1670
T: 61 2 9889 5171
ABN 73 104 285 136 (DGR Endorsed)
cysticfibrosis.org.au

28th November 2023

To whom it may concern,

RE: Endoresement for the Inclusion of Trikafta for Children Aged 2 – 5 on the PBS

I am writing to formally convey Cystic Fibrosis Australia's steadfast support for the inclusion of Trikafta for children with cystic fibrosis aged 2-5 years on the PBS. Aligning Australia with international standards and providing equitable access to CFTR modulator therapies, such as Orkambi and Symdeko, is paramount. Further, clinical data unequivocally demonstrates the safety and efficacy of Trikafta for this age group.

Given the genetic nature of cystic fibrosis, early intervention is critical to mitigate long-term decline. Access to modulator therapies, such as Trikafta have not only demonstrated a significant reduction in the burden of care on families and the healthcare systems, but also resulted in reduced hospitalization, improved lung function and a decrease on the reliance for lung transplantation. Ultimately, we know that early access to therapies supports better outcomes and enables significant improvements in the quality of life.

Early intervention is vital for the long-term health and life expectancy of the 300 children who will benefit from this listing. Beyond the immediate beneficiaries, there are significant flow-on benefits for carers and siblings that will be immense. Those currently benefiting from Trikafta have labelled it as a game-changer for people with cystic fibrosis. I urge you to approve this listing to prevent future suffering and maximize the benefits before irreversible damage is done, particularly to the lungs.

Your support for this listing holds the potential to instill hope in the hearts of young Australians grappling with cystic fibrosis, offering them the prospect of a full and healthy life.

If you need any more information, please feel free to contact me.

Yours sincerely,

Jo Armstrong
Chief Executive Officer
Cystic Fibrosis Australia